Current Opinion in Pulmonary Medicine was launched in 1995. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of pulmonary medicine is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue.
Lee Brown received the BS (1972) in Electrical Engineering from the Massachusetts Institute of Technology, USA and the MD (1976) from the Mount Sinai School of Medicine of the City University of New York, USA. He is a Clinical Professor and an Emeritus Professor of Internal Medicine at the University of New Mexico School of Medicine, USA, after having retired from UNM as a tenured Professor. Following retirement, he established and is medically directing the Sleep Institute of NM, a division of NM Oncology and Hematology Consultants. He is board certified in Internal Medicine, Pulmonary Disease, and Sleep Medicine (ABSM). His research interests include circadian rhythm disorders; sleep disordered breathing; other sleep disorders; pulmonary and sleep physiology; and pleural disease.
He previously held faculty positions at the Mount Sinai School of Medicine and the University of Arizona College of Medicine, USA. He is a member of the Eta Kappa Nu, Tau Beta Pi, and Sigma Xi honorary societies. He has been listed in Castle Connolly “Top Doctors of America” for Sleep Medicine and Pulmonary Medicine, a “Top Doctor” in U.S. News and World Report and won the Outstanding Clinician Award from the New Mexico Thoracic Society. He received the Alfred Soffer Award for Editorial Excellence from the American College of Chest Physicians (ACCP) in 2003. He has served on the Boards of Directors or Trustees of the American Thoracic Society (ATS), the American Academy of Sleep Medicine (AASM), and the Greater Albuquerque Medical Association (GAMA); he served as President of GAMA in 2008 and now is a Councilor representing GAMA to the New Mexico Medical Society and once again a member of the GAMA Board of Trustees.
Dr Brown has also been active in the American College of Chest Physicians and chaired the Sleep Network for that organization. He was appointed to the State of NM Advisory Board for Respiratory Care in 2010 and has been chairing the Board since 2014; he also chairs the Polysomnography Practice Advisory Committee of the NM Medical Board. He has served on the Editorial Board of CHEST, published by the American College of Chest Physicians, and is an Associate Editor and Founding Section Editor (Emerging Technologies) for the Journal of Clinical Sleep Medicine, co-editor of the Section on Sleep and Respiratory Neurobiology of Current Opinion in Pulmonary Medicine, and was co-editor of a 2017 volume of Sleep Medicine Clinics concerned with Advanced PAP Therapies. At last count he is the author or co-author of 147 research reports, clinical guidelines, official statements, reviews, book chapters, and editorials, all in peer reviewed media.
Winfried Johannes Randerath
After his medical studies in 1987 at the University of Duesseldorf in Germany, Dr Randerath has entered the field of pneumology with a focus on respiratory and sleep medicine. He holds the position as Medical Director at the Bethanien Hospital, Solingen, Germany, Clinic for Pneumology and Allergology, Center for Sleep Medicine and Respiratory Care as well as the position Director of the Institute of Pneumology at the University of Cologne, Germany. He is board certified in Internal Medicine, Pulmonary Disease, Allergology, Environmental Medicine, Palliative Medicine and Sleep Medicine.
He published over 300 hundred national and international papers and is Editor in Chief of Sleep Medicine and Sleep Medicine X as well as Krager Kompass Pneumologie and Associate Editor of Respiration and ERJ open Research. He is a Fellow of the American Thoracic Society, the American Association of Sleep Medicine and the American College of Chest Physicians and was awarded the Teaching Award of the European Respiratory Society and the Meier-Ewert-Price of the German Dental Sleep Medicine Society.
He is Secretary General of the German Society of Respiratory Medicine (DGP) since 2018 and has served as a board member of the German Society for Sleep Research and Sleep Medicine as well as Chair of the Northern Westphalian Society of Sleep Medicine from 2009 to 2020.
Within ERS he serves as Assembly Head of Assembly 4, Sleep Disordered Breathing since 2021. Before, he has served as Group Chair of group 4.02 Sleep and Control of Breathing from 2015 to 2018. He is a member of the ERS Adult Examination Committee since 2019 and served as a member of the ERS Guidelines Committee from 2018 to 2021. He chaired multiple ERS Task Forces: CPAP therapies (started 2022), Technical Standards (Statement finished 2022) non-CPAP therapies (Guideline finished 2021), Sleep and Stroke (Statement finished 2019), Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep (Statement finished 2016), non-CPAP therapies (Statement finished 2011) HERMES (finished 2014).
Dr Randerath chaired the congress of the German Respiratory Society in 2018, the congress of the German Society for Sleep Research and Sleep Medicine in 2007 and 2014.
His main research activities are, differentiation of obstructive and central sleep apnoea, interaction of sleep apnoea and the heart, pulmonary intensive care, chronic respiratory failure.
Dr Peter Barry undertook specialist training in Respiratory and General Internal Medicine in the Republic of Ireland. Having worked as a Clinical Research Fellow in cystic fibrosis at St. Vincent's University Hospital, Dublin, he joined the University Hospital of South Manchester and is now a Consultant Respiratory Physician in the Manchester Adult Cystic Fibrosis Centre. He is an Honorary Senior Lecturer with the University of Manchester, UK.
Dr Barry is interested in the clinical applications of novel CF therapies, and has been national and global PI on CFTR modulator trials. He has served as a clinical expert on NICE evaluations of new therapies in CF, and is the Co-Chair of the Manchester Cystic Fibrosis Conference and a member of the ECFS Scientific Committee.
Professor Barry Plant MD, FRCPI, MFSEM is a Consultant Respiratory Physician, Clinical Lead for Respiratory Medicine and the Director of the Adult CF Centre at Cork University Hospital (CUH)-University College Cork, Ireland, an executive member of the CF Registry of Ireland, and an executive board member of ECFS. A University College Cork Medical Graduate (Honours), he dual trained in Respiratory and General Medicine in accordance with the Royal College of Physicians of Ireland and subsequently undertook a Fellowship in Pulmonary and Critical Medicine at the University of Washington, Seattle, USA, with a special interest in CF, where he remained until securing his current post in 2007. He is the current Chairperson for the Royal College of Physicians of Ireland's Clinical Advisory Group (CAG) for Cystic Fibrosis, a lead author of “Cystic Fibrosis: A Model of Care for Ireland” NCP CF 2019 and the Adult Chairperson for the CF Covid NCP CF working group 2020.
Prof. Plant's research group focuses on translational medicine. In response to the Covid-19 pandemic he and his research group have established the TeCC (Telemedicine, Cystic Fibrosis, Corona-virus) study to enhance CF care. He has previously received research grant support from many funding agencies including coordinating an FP7 award from the EU commission which completed a randomised multi-centre control trial of microbiome-derived antimicrobial treatments versus current empirical therapy. Equally his research group have significant clinical and research experience in the area of CFTR modulation, inflammatory responses and Aging in CF. His group actively participate in many CF clinical trials and he has been a PI on ‘real-world’ implications of new inhaled antibiotic delivery systems multicenter groups. Recently Professor Plant was a Global PI on a triple therapy CFTR modulator in CF. He has been an invited speaker at a number of meetings including ATS, ERS, ECFC, Australasian CF Society, and an FDA meeting.